At a glance
- Originator Pharmacia Corporation
- Class Antineoplastics
- Mechanism of Action Alkylating agents; DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 05 Nov 1997 No-Development-Reported for Cancer in Italy (Unknown route)
- 15 Nov 1996 Preclinical development for Cancer in Italy (Unknown route)